- As rumored, Johnson & Johnson (NYSE:JNJ) sells its underperforming Cordis unit to Cardinal Health (CAH), which picks up the interventional vascular technology business for $1.99B. The transaction is expected to close by end of the year.
- Both stocks are unchanged premarket.
- Previously: J & J rumored to have found a buyer for Cordis unit (Feb. 23)
Recommended For You
More Trending News
See More »